Check out this week's top-performing mid-cap stocks, including Akero Therapeutics' remarkable 106.57% surge following ...

Fintel reports that on January 30, 2025, B of A Securities upgraded their outlook for Akero Therapeutics (NasdaqGS:AKRO) from ...

根据最近的一份文件显示，Akero Therapeutics, Inc. (NASDAQ: AKRO )的首席开发官Yale Catriona最近出售了大量公司股票。1月27日，Catriona总共出售了48,074股Akero Therapeutics普通股。这些股票以55.152美元至57.007美元的价格出售，总计约273万美元。

Canaccord Genuity adjusted its outlook on Akero Therapeutics (NASDAQ: NASDAQ:AKRO) shares, raising the price target to $73 ...

Jonathan Woo, an analyst from Phillip Securities, maintained the Buy rating on Akero Therapeutics (AKRO – Research Report). The associated ...

J.P. Morgan, Morgan Stanley and Jefferies are acting as joint book-running managers for the proposed offering. The securities ...

根据最近的SEC文件显示，Akero Therapeutics Inc.（纳斯达克股票代码：AKRO）商业战略高级副总裁Patrick Lamy执行了一系列涉及公司普通股的交易。1月27日，Lamy以平均57.03美元的价格出售了5,000股，总计285,150美元。这次出售是之前制定的Rule 10b5-1交易计划的一部分。这笔交易发生之际，这家市值38亿美元的生物科技公司股票显示出显著的动能， ...

Akero Therapeutics reports a 39% improvement in cirrhosis patients using EFX. See why AKRO stock is soaring with the ...

Akero Therapeutics (AKRO) reported 96-week data in its trial of advanced MASH patients, and there seem really significant ...

Akero Therapeutics, Inc. (NASDAQ:AKRO – Get Free Report) traded up 4.8% during mid-day trading on Wednesday after Morgan ...

We recently compiled a list of the 10 Firms Post Impressive Gains on Monday. In this article, we are going to take a look at ...

Roche Holding AG Akt 1.54% CHF230.28B ...